# REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct01353586` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01353586](<https://clinicaltrials.gov/study/NCT01353586>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01353586

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

## Technical summary

Registry record NCT01353586. Allocation not applicable; no masking; primary purpose treatment. Start 2011-03-01 (actual); primary completion 2013-09-01 (actual). Results posted on 2016-02-02.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Started: 2011-03-01 (actual) (ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Primary completion: 2013-09-01 (actual) (ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Completion: 2013-09-01 (actual) (ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Results first posted: 2016-02-02 (ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Countries: Belgium; Czechia; Denmark; France; Germany; Italy (ClinicalTrials.gov record NCT01353586, source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01353586-2017-06-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
- Acronym: REVOLUTION
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): nMARQ™ System
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: 2db25ecd2c652c928af4f442c44d4c4e2c579f27e6f1e43cbaff5eeb04870f10
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
